More Articles

Sustainable biosimilar policies in Europe Biosimilars/Research | Posted 31/07/2020

A review of approaches to biosimilar policy in Europe [1] highlights key principles for a sustainable biosimilar market, including supporting innovation and allowing for multiple suppliers.

US policy brief identifies barriers to biosimilars uptake Policies & Legislation | Posted 31/07/2020

It was projected that by 2026, biosimilars could save up to US$150 billion in the specialty pharmaceuticals market. However, in the US, it has emerged that there are inherent barriers to market ent...

EC approval for Sanofi’s insulin aspart biosimilar Biosimilars/News | Posted 31/07/2020

The European Commission (EC) has issued marketing authorization for Sanofi’s insulin aspart biosimilar, which references Novo Nordisk’s product NovoLog and is used to treat type 1 and 2 diabetes.

Genentech and Amgen settle biosimilar disputes Policies & Legislation | Posted 31/07/2020

Genentech has reached a settlement agreement with Amgen over its biosimilars of Herceptin (trastuzumab) and Avastin (bevacizumab). All claims have been dismissed, allowing Amgen to continue marketi...

Biosimilar infliximab uptake in Canada Reports | Posted 31/07/2020

The first biosimilar infliximab was sold in Canada in 2015, yet by 2018 uptake was still less then 10%, data from the Patented Medicine Prices Review Board (PMPRB) reveal.

Study reveals link between socioeconomic status and brand-name prescriptions Generics/Research | Posted 31/07/2020

A link between socioeconomic status and the prescription of brand-name drugs in the US, has been revealed by a team of researchers based at Brown University [1].

Biosimilar infliximab reduces medication costs by two thirds in Finland Biosimilars/Research | Posted 31/07/2020

A study of 54 people with inflammatory bowel disease (IBD) in Finland showed that switching to biosimilar infliximab has no significant impact on health-related quality of life or disease activity,...

Generics reform in Korea Guidelines | Posted 31/07/2020

The Korean Ministry of Food and Drug Safety (MFDS) has taken action to improve the quality of generic drug products and ensure an efficient and competitive generics market.